BAY59-7939 Japanese in Atrial Fibrillation (2nd)

• Status: Completed
• Trial end date: 2006-03-01

Summary

This study was a randomized, parallel group, open label trial using warfarin as comparator. Pharmacokinetics (PK) and pharmacodynamics (PD) were investigated only in BAY59-7939 groups (originally described in Japanese).

• Phase: Phase 2

Details

• Lead Sponsor: Bayer
• Treatments: Rivaroxaban; Warfarin